2024
Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell- and Tissue-Based TherapyGraft RejectionHumansImmunomodulationOrgan TransplantationConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejection
2023
Cellular activation pathways and interaction networks in vascularized composite allotransplantation
Knoedler L, Knoedler S, Panayi A, Lee C, Sadigh S, Huelsboemer L, Stoegner V, Schroeter A, Kern B, Mookerjee V, Lian C, Tullius S, Murphy G, Pomahac B, Kauke-Navarro M. Cellular activation pathways and interaction networks in vascularized composite allotransplantation. Frontiers In Immunology 2023, 14: 1179355. PMID: 37266446, PMCID: PMC10230044, DOI: 10.3389/fimmu.2023.1179355.Peer-Reviewed Original ResearchConceptsVascularized Composite AllotransplantationComposite allotransplantationRecipient-derived lymphocytesTreatment of patientsCellular activation pathwaysMultidrug immunosuppressionVCA graftsVCA patientsVCA rejectionGraft rejectionDevastating injuriesClinical managementNovel therapiesReconstructive surgeryLimb lossRejection responseFacial disfigurementAllotransplantationPatientsGraftActivation pathwayTissue cellsDifferent cell typesTissue typesCell typesCorrelation between facial vascularized composite allotransplantation rejection and laboratory markers: Insights from a retrospective study of eight patients
Kauke-Navarro M, Knoedler S, Panayi A, Knoedler L, Haller B, Parikh N, Huelsboemer L, Stoegner V, Kiefer J, Eisenhardt S, Azzi J, Pomahac B. Correlation between facial vascularized composite allotransplantation rejection and laboratory markers: Insights from a retrospective study of eight patients. Journal Of Plastic Reconstructive & Aesthetic Surgery 2023, 83: 155-164. PMID: 37276734, DOI: 10.1016/j.bjps.2023.04.050.Peer-Reviewed Original ResearchInsights from immunoproteomic profiling of a rejected full-face transplant
Lee C, Wang D, Kauke-Navarro M, Russell-Goldman E, Xu S, Mucciarone K, Sohrabi S, Lian C, Pomahac B, Murphy G. Insights from immunoproteomic profiling of a rejected full-face transplant. American Journal Of Transplantation 2023, 23: 1058-1061. PMID: 37037378, DOI: 10.1016/j.ajt.2023.04.008.Peer-Reviewed Original ResearchConceptsVascularized Composite AllograftsT cellsChronic rejectionCD8-positive T cellsEffector T cellsFull face transplantArteriosclerotic alterationsIntragraft arteriesVCA rejectionGraft arteryAccelerated arteriosclerosisRecipient originPunch biopsyAtherogenic responseComposite allograftsImmunoproteomic profilingDioxygenase 1Target endotheliumArteryEndotheliumProteomic profilingPathway componentsCellsRejectionAllograftsLow-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study
Murakami N, Borges T, Win T, Abarzua P, Tasigiorgos S, Kollar B, Barrera V, Ho Sui S, Teague J, Bueno E, Clark R, Lian C, Murphy G, Pomahac B, Riella L. Low-dose interleukin-2 promotes immune regulation in face transplantation: A pilot study. American Journal Of Transplantation 2023, 23: 549-558. PMID: 36740193, PMCID: PMC10318113, DOI: 10.1016/j.ajt.2023.01.016.Peer-Reviewed Original ResearchMeSH KeywordsFacial TransplantationGraft RejectionHumansInterleukin-2Pilot ProjectsT-Lymphocytes, RegulatoryConceptsLow-dose IL-2 therapyIL-2 therapySkin allograftsFace transplant recipientsTransplant recipientsIL-2Immune regulationLow-dose interleukin-2 (IL-2) therapyHigher acute rejection ratesLow-dose IL-2Face transplantationAcute rejection ratesCytotoxicity-associated genesDose interleukin-2Greater suppressive functionInterleukin-2 therapyAutoimmune hemolytic anemiaRegulatory T cellsNarrow therapeutic windowLife-changing procedureImmunological monitoringTim-3Peripheral bloodImmune modulationHemolytic anemia
2022
Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA
Kauke-Navarro M, Knoedler S, Panayi AC, Knoedler L, Noel OF, Pomahac B. Regulatory T Cells: Liquid and Living Precision Medicine for the Future of VCA. Transplantation 2022, 107: 86-97. PMID: 36210500, DOI: 10.1097/tp.0000000000004342.Peer-Reviewed Original ResearchMeSH KeywordsGraft RejectionImmune TolerancePrecision MedicineT-Lymphocytes, RegulatoryVascularized Composite AllotransplantationConceptsSolid organ transplantationOrgan transplantationSide effectsField of VCAMedication side effectsBeneficial clinical effectsChimeric antigen receptorSevere side effectsRisk of infectionT cell receptorMaintenance immunosupressionMetabolic complicationsClinical effectsTransplant rejectionLifelong immunosuppressionImmune cellsTregsComposite allotransplantationSpecific antigenTherapeutic efficacyAntigen receptorStable levelPrecision medicineImmune system mechanismsImmunotolerance
2021
Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection
Win T, Crisler W, Dyring-Andersen B, Lopdrup R, Teague J, Zhan Q, Barrera V, Sui S, Tasigiorgos S, Murakami N, Chandraker A, Tullius S, Pomahac B, Riella L, Clark R. Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection. Journal Of Clinical Investigation 2021, 131 PMID: 33667197, PMCID: PMC8262560, DOI: 10.1172/jci135166.Peer-Reviewed Original ResearchConceptsVCA rejectionTransplant rejectionT cellsTissue injuryGene expression profilingAntigen-presenting cell activationT-cell receptor sequencingSolid organ transplantsCell receptor sequencingT cell activation pathwaysAntigen-specific activationProliferative T cellsCell activation pathwaysNovo Nordisk FoundationAmerican SocietyExpression profilingFace transplant patientsTransplant patientsImmunologic pathwaysImmunoregulatory networkSkin biopsiesImmunomodulatory pathwaysLimb transplantsLundbeck FoundationTransplant Research
2020
Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review
Safi AF, Kauke M, Nelms L, Palmer WJ, Tchiloemba B, Kollar B, Haug V, Pomahač B. Local immunosuppression in vascularized composite allotransplantation (VCA): A systematic review. Journal Of Plastic Reconstructive & Aesthetic Surgery 2020, 74: 327-335. PMID: 33229219, DOI: 10.1016/j.bjps.2020.10.003.Peer-Reviewed Original ResearchConceptsLocal immunosuppressionSystematic reviewAllograft survivalComposite allotransplantationAllograft survival dataCell-based therapy strategiesImproved allograft survivalMain immunosuppressive agentMeta-Analyses (PRISMA) guidelinesPreclinical animal studiesPreferred Reporting ItemsMalignant side effectsImmunosuppressive agentsPreclinical dataSignificant prolongationRat modelHuman trialsExclusion criteriaImmunosuppressionSide effectsAnimal studiesReporting ItemsPubMed databaseSystemic toxicityTherapy strategiesCirculating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation?
Haug V, Kuang Y, Tasigiorgos S, Kollar B, Mogili A, Jänne P, Talbot S, Paweletz C, Pomahac B. Circulating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation? Transplantation 2020, 104: e79-e80. PMID: 31596743, DOI: 10.1097/tp.0000000000003000.Peer-Reviewed Original Research
2019
Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation
Shubin A, Kollar B, Dillon S, Pomahac B, Libermann T, Riella L. Blood proteome profiling using aptamer-based technology for rejection biomarker discovery in transplantation. Scientific Data 2019, 6: 314. PMID: 31819064, PMCID: PMC6901551, DOI: 10.1038/s41597-019-0324-y.Peer-Reviewed Original ResearchMeSH KeywordsAptamers, NucleotideBiomarkersBlood ProteinsGraft RejectionHumansProteomeProteomicsTransplantationConceptsDevastating facial injuriesSevere rejection episodesAcute transplant rejectionType of transplantationPeripheral blood serumSOMAscan proteomics platformSatisfactory treatment optionAcute rejectionRejection episodesTransplant statusTransplantation centersTransplant rejectionTreatment optionsBiomarker discoverySkin biopsiesClinical dataHigh riskFacial injuriesInvasive biomarkersTransplantationAptamer-based technologiesFace transplantationPatientsBlood serumSerum proteinsThe Evolving Clinical Presentation of Acute Rejection in Facial Transplantation
Haug V, Kollar B, Obed D, Kiwanuka H, Turk M, Wo L, Tasigiorgos S, Kueckelhaus M, Riella L, Pomahac B. The Evolving Clinical Presentation of Acute Rejection in Facial Transplantation. Facial Plastic Surgery & Aesthetic Medicine 2019, 21: 278-285. PMID: 30998810, PMCID: PMC6646986, DOI: 10.1001/jamafacial.2019.0076.Peer-Reviewed Original ResearchConceptsAcute rejectionSubtherapeutic tacrolimus levelsClinical signsRejection episodesImmunosuppressive therapySubclinical rejectionTacrolimus levelsMedical recordsOdds ratioFacial transplantationDiagnostic valueSignificant associationSingle-center cohort studyLate rejection episodesProtocol skin biopsiesSecond posttransplant yearSymptoms of rejectionTacrolimus blood levelsSecond postoperative yearReliable clinical signFull facial transplantationPostoperative yearPosttransplant yearYears posttransplantationAllograft rejectionFive-Year Follow-up after Face Transplantation
Tasigiorgos S, Kollar B, Turk M, Perry B, Alhefzi M, Kiwanuka H, Nizzi M, Marty F, Chandraker A, Tullius S, Riella L, Pomahac B. Five-Year Follow-up after Face Transplantation. New England Journal Of Medicine 2019, 380: 2579-2581. PMID: 31141626, DOI: 10.1056/nejmc1810468.Peer-Reviewed Original Research
2018
Chronic rejection of human face allografts
Krezdorn N, Lian C, Wells M, Wo L, Tasigiorgos S, Xu S, Borges T, Frierson R, Stanek E, Riella L, Pomahac B, Murphy G. Chronic rejection of human face allografts. American Journal Of Transplantation 2018, 19: 1168-1177. PMID: 30312535, PMCID: PMC6433509, DOI: 10.1111/ajt.15143.Peer-Reviewed Original ResearchConceptsChronic rejectionComposite allograftsAutoimmune cutaneous disordersImmune-mediated changesLymphocyte-mediated cytotoxicityC-fosSevere facial disfigurementType IAcute rejectionSurveillance biopsiesIatrogenic immunosuppressionVascular ectasiaFollicular pluggingSystemic sclerosisHistopathologic evidenceClinical manifestationsPreventative therapyCutaneous disordersGraft durabilityFace allograftNasal mucosaPathologic changesPathologic alterationsEpidermal thinningSclerotic zoneIncreased levels of circulating MMP3 correlate with severe rejection in face transplantation
Kollar B, Shubin A, Borges T, Tasigiorgos S, Win T, Lian C, Dillon S, Gu X, Wyrobnik I, Murphy G, Pomahac B, Libermann T, Riella L. Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Scientific Reports 2018, 8: 14915. PMID: 30297859, PMCID: PMC6175842, DOI: 10.1038/s41598-018-33272-7.Peer-Reviewed Original ResearchConceptsSevere rejectionFace transplantationLarge independent patient cohortsAcute rejection episodesAnti-rejection treatmentFirst postoperative yearLongitudinal serum samplesNon-invasive candidate biomarkersViable treatment optionSOMAscan proteomics platformIndependent patient cohortsFace transplant recipientsRejection episodesPostoperative yearTransplant recipientsDevastating injuriesMMP3 levelsTransplant rejectionHistological gradePatient cohortTreatment optionsSurrogate markerMMP3 proteinCandidate biomarkersTransplantationInnovations in reconstructive microsurgery: Reconstructive transplantation
Kollar B, Tasigiorgos S, Dorante M, Carty M, Talbot S, Pomahac B. Innovations in reconstructive microsurgery: Reconstructive transplantation. Journal Of Surgical Oncology 2018, 118: 800-806. PMID: 30098294, DOI: 10.1002/jso.25147.Peer-Reviewed Original ResearchMeSH KeywordsForecastingGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsMicrosurgeryOrgan TransplantationConceptsReconstructive transplantationViable reconstructive optionPediatric transplantsUpper extremityLower extremitiesAbdominal wallReconstructive optionsAdditional proceduresReconstructive microsurgeryTransplantationFace transplantTransplantPresent review articleExtremitiesReview articlePatientsUterusNeck
2017
Seasonal Variability Precipitating Hand Transplant Rejection?
Lopdrup R, Turk M, Win T, Marty F, Molway D, Tullius S, Pomahac B, Talbot S. Seasonal Variability Precipitating Hand Transplant Rejection? Transplantation 2017, 101: e313. PMID: 28930103, DOI: 10.1097/tp.0000000000001877.Peer-Reviewed Original ResearchNew Avenues of Vascularized Composite Allotransplantation and their Potential Risks and Benefits
Tasigiorgos S, Krezdorn N, Bueno E, Pomahac B. New Avenues of Vascularized Composite Allotransplantation and their Potential Risks and Benefits. Annals Of Surgery 2017, 266: e25. PMID: 28525412, DOI: 10.1097/sla.0000000000002294.Peer-Reviewed Original Research
2016
Immunological Characteristics of a Patient With Belatacept‐Resistant Acute Rejection After Face Transplantation
Krezdorn N, Murakami N, Pomahac B, Riella L. Immunological Characteristics of a Patient With Belatacept‐Resistant Acute Rejection After Face Transplantation. American Journal Of Transplantation 2016, 16: 3305-3307. PMID: 27457067, PMCID: PMC5087655, DOI: 10.1111/ajt.13977.Peer-Reviewed Original ResearchCodominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients
Borges T, O'Malley J, Wo L, Murakami N, Smith B, Azzi J, Tripathi S, Lane J, Bueno E, Clark R, Tullius S, Chandraker A, Lian C, Murphy G, Strom T, Pomahac B, Najafian N, Riella L. Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients. American Journal Of Transplantation 2016, 16: 2158-2171. PMID: 26749226, PMCID: PMC4979599, DOI: 10.1111/ajt.13705.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibody developmentDe novo donor-specific antibodiesInterleukin-17-producing T cellsT helper 2 cell phenotypeFacial transplantationDonor-specific antibody developmentNovo donor-specific antibodiesChemotactic protein-1 levelsPeripheral blood mononuclear cellsAcute cellular rejectionAnti-HLA antibodiesDonor-specific antibodiesFollicular helper cellsImmune cell subsetsProtein-1 levelsBlood mononuclear cellsMedium-term outcomesSkin biopsy specimensFull facial transplantationCellular rejection processLife-changing procedureCellular rejectionCodominant roleDonor alloreactivityTransplant recipients
2015
Noninvasive Monitoring of Immune Rejection in Face Transplant Recipients
Kueckelhaus M, Imanzadeh A, Fischer S, Kumamaru K, Alhefzi M, Bueno E, Wake N, Gerhard-Herman M, Rybicki F, Pomahac B. Noninvasive Monitoring of Immune Rejection in Face Transplant Recipients. Plastic & Reconstructive Surgery 2015, 136: 1082-1089. PMID: 26505709, DOI: 10.1097/prs.0000000000001703.Peer-Reviewed Original ResearchConceptsFace transplant recipientsTransplant recipientsChronic rejectionCLINICAL QUESTION/LEVELAllograft biopsy specimensTotal vessel diameterSolid organ allograftsAllograft lossOrgan allograftsPostsurgical monitoringFlap arteryControl subjectsBiopsy specimensIntimal thicknessClinical signsRadial arteryThicker intimaUltrasound biomicroscopyFacial arteryMedia thicknessHistologic analysisImmune rejectionArteryRecipientsInterobserver correlation